Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)’s share price traded up 2.2% during trading on Friday . The company traded as high as $90.86 and last traded at $90.07, with a volume of 741,126 shares traded. The stock had previously closed at $88.15.

A number of equities analysts have commented on the company. Robert W. Baird reaffirmed an “outperform” rating and issued a $128.00 price target (down from $144.00) on shares of Vertex Pharmaceuticals in a research note on Sunday, May 1st. Stifel Nicolaus reduced their target price on Vertex Pharmaceuticals from $140.00 to $108.00 and set a “buy” rating on the stock in a research note on Friday, April 1st. Maxim Group reissued a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Thursday, April 28th. BMO Capital Markets began coverage on Vertex Pharmaceuticals in a research note on Thursday, April 7th. They set a “market perform” rating and a $90.00 target price on the stock. Finally, Jefferies Group reissued a “buy” rating and set a $116.00 target price on shares of Vertex Pharmaceuticals in a research note on Sunday, March 27th. Eight investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $125.11.

The firm’s market cap is $22.31 billion. The stock’s 50-day moving average price is $89.32 and its 200 day moving average price is $89.25.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Wednesday, April 27th. The pharmaceutical company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.29 by $0.20. The firm earned $398.10 million during the quarter, compared to analysts’ expectations of $439.94 million. During the same quarter last year, the firm posted ($0.62) EPS. The business’s revenue for the quarter was up 187.4% on a year-over-year basis. On average, analysts predict that Vertex Pharmaceuticals Inc. will post $1.03 EPS for the current year.

In other Vertex Pharmaceuticals news, Director Joshua S. Boger sold 5,130 shares of the firm’s stock in a transaction on Wednesday, April 27th. The stock was sold at an average price of $83.67, for a total transaction of $429,227.10. Following the transaction, the director now directly owns 270,414 shares in the company, valued at approximately $22,625,539.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Paul M. Silva sold 3,000 shares of the firm’s stock in a transaction on Monday, May 9th. The stock was sold at an average price of $87.63, for a total value of $262,890.00. Following the transaction, the senior vice president now owns 15,950 shares in the company, valued at $1,397,698.50. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. increased its position in Vertex Pharmaceuticals by 0.9% in the fourth quarter. Ameritas Investment Partners Inc. now owns 8,698 shares of the pharmaceutical company’s stock valued at $1,094,000 after buying an additional 78 shares during the last quarter. Turner Investments L.P. purchased a new position in Vertex Pharmaceuticals during the fourth quarter valued at approximately $1,095,000. Robeco Institutional Asset Management B.V. increased its position in Vertex Pharmaceuticals by 32.1% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 10,728 shares of the pharmaceutical company’s stock valued at $1,350,000 after buying an additional 2,605 shares during the last quarter. Greenwood Capital Associates LLC increased its position in Vertex Pharmaceuticals by 0.7% in the fourth quarter. Greenwood Capital Associates LLC now owns 10,768 shares of the pharmaceutical company’s stock valued at $1,355,000 after buying an additional 80 shares during the last quarter. Finally, Gratus Capital LLC purchased a new position in Vertex Pharmaceuticals during the fourth quarter valued at approximately $1,858,000.

Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.